| Identification | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Sargramostim | |||||||||||||||
| Accession Number | DB00020 (BIOD00035, BTD00035) | |||||||||||||||
| Type | biotech | |||||||||||||||
| Groups | approved | |||||||||||||||
| Description | Human, recombinant GM-CSF, expressed in yeast. Glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein. |
|||||||||||||||
| Protein structure |
Display: 3D Structure |
|||||||||||||||
| Protein chemical formula | C639H1006N168O196S8 | |||||||||||||||
| Protein average weight | 14434.5000 | |||||||||||||||
| Sequences |
>DB00020 sequence APARSPSPSTQPWEHVNAIQEALRLLNLSRDTAAEMNETVEVISEMFDLQEPTCLQTRLE LYKQGLRGSLTKLKGPLTMMASHYKQHCPPTPETSCATQIITFESFKENLKDFLLVIPFD CWEPVQE FASTA |
|||||||||||||||
| Synonyms |
|
|||||||||||||||
| Salts | Not Available | |||||||||||||||
| Brand names |
|
|||||||||||||||
| Brand mixtures | Not Available | |||||||||||||||
| Categories |
|
|||||||||||||||
| CAS number | 83869-56-1 | |||||||||||||||
| Taxonomy | ||||||||||||||||
| Kingdom | Not Available | |||||||||||||||
| Classes | Not Available | |||||||||||||||
| Substructures | Not Available | |||||||||||||||
| Pharmacology | ||||||||||||||||
| Indication | For the treatment of cancer and bone marrow transplant | |||||||||||||||
| Pharmacodynamics | Sargramostim is used in the treatment of bone marrow transplant recipients or those exposed to chemotherapy an recovering from acut myelogenous leukemia, Leukine or GM-CSF is a hematopoietic growth factor which stimulates the survival, clonal expansion (proliferation) and differentiation of hematopoietic progenitor cells. GM-CSF is also capable of activating mature granulocytes and macrophages. After a bone marrow transplant or chemotherapy, patients have a reduced capacity to produce red and white blood cells. Supplementing them with external sources of GM-CSF helps bring the level of neutrophils back to normal so that they can better fight infections. | |||||||||||||||
| Mechanism of action | Sargramostim binds to the Granulocyte-macrophage colony stimulating factor receptor (GM-CSF-R-alpha or CSF2R) which stimulates a JAK2 STAT1/STAT3 signal transduction pathway. This leads to the production of hemopoietic cells and neutrophils | |||||||||||||||
| Absorption | Not Available | |||||||||||||||
| Volume of distribution | Not Available | |||||||||||||||
| Protein binding | Not Available | |||||||||||||||
| Metabolism | Not Available | |||||||||||||||
| Route of elimination | Not Available | |||||||||||||||
| Half life | Not Available | |||||||||||||||
| Clearance |
|
|||||||||||||||
| Toxicity | Not Available | |||||||||||||||
| Affected organisms |
|
|||||||||||||||
| Pathways | Not Available | |||||||||||||||
| Pharmacoeconomics | ||||||||||||||||
| Manufacturers | Not Available | |||||||||||||||
| Packagers | ||||||||||||||||
| Dosage forms |
|
|||||||||||||||
| Prices |
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational
purposes only.
|
|||||||||||||||
| Patents |
|
|||||||||||||||
| Properties | ||||||||||||||||
| State | liquid | |||||||||||||||
| Experimental Properties |
|
|||||||||||||||
| References | ||||||||||||||||
| Synthesis Reference | Not Available | |||||||||||||||
| General Reference | Not Available | |||||||||||||||
| External Links |
|
|||||||||||||||
| ATC Codes |
|
|||||||||||||||
| AHFS Codes | Not Available | |||||||||||||||
| PDB Entries | ||||||||||||||||
| FDA label | Not Available | |||||||||||||||
| MSDS | Not Available | |||||||||||||||
| Interactions | ||||||||||||||||
| Drug Interactions | Not Available | |||||||||||||||
| Food Interactions | Not Available | |||||||||||||||
| Targets |
|---|
|
1. Granulocyte-macrophage colony-stimulating factor receptor alpha chain Pharmacological action: yesActions: agonist Low affinity receptor for granulocyte-macrophage colony- stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells Organism class: humanUniProt ID: P15509 ![]() Gene: CSF2RA ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
2. Interleukin-3 receptor alpha chain Pharmacological action: yesActions: agonist This is a receptor for interleukin-3 Organism class: humanUniProt ID: P26951 ![]() Gene: IL3RA ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
3. Cytokine receptor common beta chain Pharmacological action: yesActions: agonist High affinity receptor for interleukin-3, interleukin-5 and granulocyte-macrophage colony-stimulating factor Organism class: humanUniProt ID: P32927 ![]() Gene: CSF2RB ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
4. Syndecan-2 Pharmacological action: unknownActions: agonist Cell surface proteoglycan that bears heparan sulfate Organism class: humanUniProt ID: P34741 ![]() Gene: SDC2 ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
Pharmacological action: unknown
Cytotoxin and helminthotoxin. Also induces non-cytolytic histamine release from human basophils. Involved in antiparasitic defense mechanisms and immune hypersensitivity reactions. The proform acts as a proteinase inhibitor, reducing the activity of PAPPA Organism class: humanUniProt ID: P13727 ![]() Gene: PRG2 ![]() Protein Sequence: FASTA Gene Sequence: FASTA SNPs: SNPJam Report ![]() References:
|
| Comments |
|---|